Prohost Portfolio PLUS #2 Re-Working Some Evaluated Biotechnology Firms Exelixis: 2020 and 2021 Wondering why Exelixis’ (EXEL) stock has looked paralyzed for more than two years? To know better about Exelixis the entrepreneur and Exelixis the creative scientific institution, we decided to go to the recorded Exelixis history, financial results and scientific . . . This content is for paid subscribers. Please click here to subscribe …

Prohost Portfolio PLUS (formerly The Week in Review) Your Questions, Our Answers In the upcoming issues of Prohost Portfolio PLUS, as with all our Tables, we will include observations and target changes as well as any current news we feel is important enough to be reviewed and/or discussed. We hope you will visit us weekly for updates. Included in this Issue are the Following: Anixa …

Prohost Letter #445 A Flashback and Future Projections 1. A Follow-Up on Recently Posted News from ProhostBiotech 2. Answering Questions 3. Development-Stage Firms to Outperform 4. Oversold Revenue-Generating Firms 5. Tables with FAIR 2021 Targets for the Prohost Selected Firms In This Issue We Discuss the Following Firms: Anixa Biosciences (

Prohost Letter #444 The End of the Year Issue was delayed because our 2020 Prohost Portfolio stocks’ targets for the year failed to materialize; nobody not even the authorities were capable of predicting the pandemic, which continues to plague the world. As 2021 approached, we were unable to the End of the Year issue on time as we lacked the information required for the fair …

Prohost Letter #443 The Biotechnology Industry The Biotechnology Industry revolutionized the arts of life sciences with accomplishments promising a tremendous improvement in the treatment of chronic, debilitating, progressive and life-threatening diseases. The improved approaches have been game changers in the treatment of cancers and genetic-derived hereditary and non-hereditary chronic diseases. The out-performance was made possible through the biotech industry’s creativity, innovation and remarkable productivity. The …

Prohost Letter 442 The Whole World Against the Blind SARS-CoV-2 Virus Investors have no doubt profited from the developers of COVID-19 vaccines which include: Moderna (MRNA), Novavax (

Prohost Letter #441 Biotechnology Companies’ Evaluations Are We Saying Goodbye to Common Sense? The SARS-CoV-2 Vaccines It is said that the difference between the SARS-CoV-2 coronavirus (COVID-19), which is causing the pandemic around the world we are currently suffering from, and other coronaviruses like SARS and/or MERS is that SARS-CoV-2 ability to replicate in the human bodies' respiratory system’s upper airways more than the others. …

The Week in Review #51 Questions & Answers About CytomX Q: Is there any reason for the CytomX stock selloff that occurred in early May? In order to answer this question we need to explain CytomX’s (CTMX) Probody therapeutics. These novel treatments are designed to remain inactive until they are activated only . . . This content is for paid subscribers. Please click here to subscribe …

Prohost Letter #440 Coronavirus The Therapeutics Gilead’s Remdesivir Treating COVID-19 patients requires therapeutic products that can deal with moderate and severe persistent symptoms that are unwilling to ease or completely disappear after weeks of isolation, when following the distancing and wearing masks. The first product proven effective and safe to be granted FDA Emergency Use Approval (EUA) happens to be remdesivir from Gilead Sciences (

The Week in Review #50 The World FOCUS is COVID-19 The world FOCUS right now is on life-saving accomplishments for COVID-19. In addition to safety measures that are being adopted by most citizens the following realizations that accomplishments might lead to a clear victory over the life-threatening novel coronavirus. They are: Successful Treatments that will alleviate the severity of symptoms from COVID-19 that is causing …

The Week in Review #49 The Stars from the Weeks Preceding the Novel Coronavirus Outbreak  Forty Seven Forty Seven (FTSV) was added to the

Prohost Letter #439 The Coronavirus Outbreak - COVID-19 The news announced that the coronavirus (now known as COVID-19) outbreak would affect not only people’s health and survival but the world’s economy, Wall Street’s performance, and especially the international giant industrial firms that are committed to China. British AstraZeneca (AZN

Prohost Letter #438 End of the Year Issue  2019 Happy New Year 2020 The NASDAQ reached 9000 for the first time in the market history on December 30, 2019. However, on the last trading day of 2019, the Nasdaq Composite Index closed at 8,945.99 after giving back 60.62 points or 0.7%. During the departed year, however, the stock exchange was boosted by the outperformance of …

The Week in Review #48 Holiday Edition ******************** Merry Christmas and Happy Hanukkah! We Wish You a Happy New Year Filled with Excellent Health, Peace of Mind, Prosperity and Happiness What a Year for Biotechnology What happened in the biotech sector toward the end of 2019 is briefed in this Review as we focus on the performance of our picked firms’ stocks’ prices. We will …

Prohost Letter #437 An All Time High Market More Prohost Picks Have Reached the 2019 Targets The stock market performance has reached an all-time high with more of our picks reaching or nearing the Prohost 2019 price targets. There are stories to tell about some devastated stocks which many believed were dead and buried but were surprisingly resurrected, and their stocks are going up. Another …

The Week in Review #47 What A Week For Biotechnology Synopsis In this “Week in Review” there is no complicated scientific and clinical information, leaving the details to the articles that we usually post on the Prohost website. Most of the Prohost picked firms’ Q3 financial results have beaten expectations. Three firms have reached the Prohost 2019 targets, and more firms have outperformed, with some …

The Week in Review #46 The Quarterly Financial Results The quarterly financial results that analysts and investors relied on for years to evaluate biotech firms, including development stage firms, seem to change. Investors have finally realized that development-stage firms have no marketed drugs and no revenues, hence, no incomes and should be evaluated based on the clinical trial results of their pipeline products. They saw …

The Week in Review #44 Quarterly Financial Results What Was Seen and What Was Ignored History and self-experiences enabled investors to expect and swallow biased reactions following the announcements of the biotech sector’s firms’ quarterly results. Investors have long been expecting negative reactions towards small development-stage biotech firms following the announcement of their quarterly financial results. What they did not expect is for the same …

The Week in Review #43 This Past Week After hearing hints about the trade war between China and the United States being avoided the market reversed course from faltering to flying at the speed of light. This trade war replaced all important factors that would usually affect the market performances. Unemployment is the lowest since 1969 and is expected to cause a bullish market, but …

The Week in Review #42 During the Departed Week The week started with the market losing over 1000 points and ended recuperating a large extent of the losses. Desperate during the market’s plummeting, some investors were happy for the rebound and some were confused and skeptical about what the unpredictable market might bring next. In the latest Prohost Letter #436, the losses in prices of …